Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lidocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A known ✓ | Q9NY46 | 3/20 | 0.97 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.97 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.97 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.97 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.55 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | MC4R | P32245 | 1/20 | 0.97 |
| ▸ | MC3R | P41968 | 1/20 | 0.97 |
| ▸ | HTR3A | P46098 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.94 |
| ▸ | GAA | P10253 | 2/20 | 0.94 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lidocaine SCHEMBL5334354 | 0.98 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL15689 | 0.98 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL8183082 | 0.98 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL8377228 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL31031037 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL13726485 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL17422676 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL29130 | 0.97 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL14782152 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL27840048 | 0.97 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137447-A1 | BUFFERED LIDOCAINE INJECTABLE FORMULATIONS AND METHODS FOR MAKING SAME | HIKMA PHARMACEUTICALS USA INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240197621-A1 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | HIKMA PHARMACEUTICLAS USA INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024137447-A1 | BUFFERED LIDOCAINE INJECTABLE FORMULATIONS AND METHODS FOR MAKING SAME | HIKMA PHARMACEUTICALS USA INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240197621-A1 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | HIKMA PHARMACEUTICLAS USA INC. | 2024-06-20 | — | — | US | disclosed |
| US-20230049330-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | WELLSMART TECHNOLOGIES INC. | 2023-02-16 | — | — | US | disclosed |
| EP-4114372-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | Neucures, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115243683-A | Use of QX314 to prevent sympathetic excitation associated with administration of TRPV1 modulators | 纽克尔斯有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-113396139-A | Aryl amide compound based on benzene ring supermolecule interaction, self-assembly form and application | 易天奇 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021178471-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | NEUCURES, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021142577-A1 | ARYLAMIDE COMPOUND BASED ON BENZENE RING SUPRAMOLECULAR INTERACTION, SELF-ASSEMBLY MORPHOLOGY, AND USE | 易天奇 | 2021-07-22 | — | — | WO | disclosed |
| EP-2203192-A1 | WOUND CARE FORMULATION | Northern Health And Social Care Trust (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037500-A1 | WOUND CARE FORMULATION | NORTHERN HEALTH AND SOCIAL CARE TRUST (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049330-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | TRPV1, TRPV4, TRPV3 | SCN3A 54/4885SCN4A 68/4885SCN5A 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.